SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Other Noncurrent Assets
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Other Noncurrent Assets of $2.42 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2020-11-06
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2020-09-30 was $1.24M, a 123900.00% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2020-06-30 was $1.18M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2019-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2019 was $141.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2018 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2017 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2020-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.42M derived: sum of 2 quarters · filed 2020-11-06 | $2.42M 10-Q · filed 2020-11-06 | $2.42M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $1.18M 10-Q · filed 2020-08-17 | $1.18M derived: sum of 3 quarters · filed 2020-08-17 | $1.18M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $1.00K derived: sum of 3 quarters · filed 2020-11-06 | -$55.00K derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $1.00K derived: sum of 2 quarters · filed 2020-11-06 | -$55.00K derived: sum of 3 quarters · filed 2020-11-06 | $141.00K 10-K · filed 2020-02-28 |
| 2019-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$55.00K derived: sum of 2 quarters · filed 2020-11-06 | $141.00K 10-Q · filed 2020-11-06 | -$201.00K derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | -$56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $140.00K 10-Q · filed 2020-08-17 | -$202.00K derived: sum of 3 quarters · filed 2020-08-17 | -$202.00K derived: sum of 4 quarters · filed 2020-08-17 |
| 2019-03-31 | $196.00K 10-Q · filed 2020-05-15 | -$146.00K derived: sum of 2 quarters · filed 2020-05-15 | -$146.00K derived: sum of 3 quarters · filed 2020-05-15 | -$146.00K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | -$342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$342.00K derived: sum of 2 quarters · filed 2020-02-28 | -$342.00K derived: sum of 3 quarters · filed 2020-02-28 | $0.00 10-K · filed 2020-02-28 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $342.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $342.00K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $342.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |